CymaBay Therapeutics financials at a glance
| Year | Year | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2013 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rev. | Revenue |
|
$0.00M | $0.00M | $0.00M | $10.00M | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M | $31.07M | $0.00M |
| GM % | Gross Margin % |
|
0.00% | 0.00% | 0.00% | -20.04% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -160.03% | 0.00% |
| OM | Operating Margin |
|
0.00% | 0.00% | 0.00% | -213.25% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | Earnings Per Share |
|
$-2.65 | $-0.82 | $-1.14 | $-0.79 | $-1.25 | $-1.46 | $-0.75 | $-1.27 | $-1.21 | $-0.99 | $0.00 | |
| Div. | Dividends |
|
$0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| PR % | Payout Ratio % |
|
0 | 0 | 0 | 0 | -0.00% | -0.00% | 0 | 0 | 0 | 0 | -0.00% | 0 |
| Sha. | Shares |
|
14.69m | 23.45m | 23.45m | 43.86m | 59.44m | 68.7m | 68.89m | 84.67m | 0m | 84.67m | 113.4m | 0m |
| OCF | Operating Cash Flow |
|
$-21.11M | $-23.32M | $-23.35M | $-19.63M | $-54.94M | $-97.91M | $-44.73M | $-69.43M | $-8.46M | $-84.08M | $-72.53M | $0.00M |
| FCF | Free Cash Flow |
|
$-21.22M | $0.00M | $-23.39M | $-19.66M | $-55.47M | $-98.23M | $-44.75M | $-69.52M | $0.00M | $-84.23M | $-89.00M | $0.00M |
| FCFS | Free Cash Flow Per Share |
|
$-1.76 | $-1.23 | $-1.00 | $-0.56 | $-0.96 | $-1.47 | $-0.65 | $-0.98 | $-3.59 | $-0.96 | $-0.69 | $0.00 |